Drugs / Tadekinig alfa
Tadekinig alfa
also known as
IL-18BP · Interleukin-18-binding protein · recombinant human IL-18 binding protein · recombinant human interleukin-18 binding protein
Protein / enzyme biologic targets IL18 via inhibition
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05306080 | Apr 2022 → Jan 2028 expected | cytokine release syndrome, hemophagocytic syndrome | University of Pennsylvania | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02398435 | Feb 2015 → Jun 2016 | adult-onset Still disease | AB2 Bio Ltd. | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT03512314 | Jan 2018 → Apr 2024 | X-linked lymphoproliferative disease due to XIAP deficiency, autoinflammatory syndrome | AB2 Bio Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT03113760 | Jul 2017 → Oct 2023 | X-linked lymphoproliferative disease due to XIAP deficiency, autoinflammatory syndrome | AB2 Bio Ltd. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
All press releases naming this drug 12 releases
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tadekinig alfa | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03113760 ↗ |
| Known as | IL-18BP | “Tadekinig alfa is the drug name for recombinant human interleukin-18 binding protein (IL-18BP).” NCT02398435 ↗1“Tadekinig alfa (IL-18BP)” NCT05306080 ↗ |
| Known as | Interleukin-18-binding protein | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108054 ↗ |
| Known as | recombinant human IL-18 binding protein | “Tadekinig alfa (recombinant human IL-18 binding protein)” NCT02398435 ↗ |
| Known as | recombinant human interleukin-18 binding protein | “Tadekinig alfa is the drug name for recombinant human interleukin-18 binding protein (IL-18BP).” NCT02398435 ↗ |
| Action | Inhibit | “IL-18 inhibition, using the recombinant human IL-18 binding protein, tadekinig alfa” PMID 29472362 ↗ Feb 2018 |
| Modality | Protein / enzyme biologic | “recombinant human interleukin-18 binding protein” NCT02398435 ↗ |
| Route | Subcutaneous | “Patients received the study treatment three times a week subcutaneously.” NCT02398435 ↗ |
| Target | IL18 | “Treatment with IL-18BP will permit to inhibit the pro-inflammatory cascade triggered by IL-18” NCT02398435 ↗ |